On December 9, 2024, our team published a new Cochrane Review exploring the benefits and risks of azathioprine, a medication that affects the immune system, for people with multiple sclerosis (MS).Kudos to the amazing team: Ben Ridley, Francesco Nonino, Elisa Baldin, Ilaria Casetta, Gerardo Iuliano, Graziella Filippini.

We are excited to announce the publication of our latest network meta-analysis, "Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis", now available in the Cochrane Library.This comprehensive study explores the comparative efficacy and safety of several immunomodulatory and immunosuppressive treatments for progressive multiple sclerosis (PMS).

From September 10-13, 2024, the beautiful city of Prague hosted the 2nd Global Evidence Summit (GES 2024).

Join US - 30 May, 10:30am (CET)Join us for our webinar in occasion of World Multiple Sclerosis Day, presented with the participation of MS International Federation (MSIF).

The PEMS project (Participatory Evidence Synthesis in Multiple Sclerosis and Complementary Therapies) is conducting an international survey to identify which outcomes should be evaluated in trials of complementary therapies for people with Multiple Sclerosis (MS). Your feedback will guide future relevant research on complementary therapies.

Survey Translation - from English to French and GermanAre you a French

A systematic review on the efficacy and safety of disease-modifying drugs in relapsing-remitting multiple sclerosis, including 50 studies with 36,541 participants and 29 drugs, was recently published by our review group in the Cochrane Library. Through a network meta-analysis, both direct and indirect comparisons were considered.

International Survey on Research Priorities for Cochrane Systematic Reviews on Multiple Sclerosis In 2020, we started an international priority-setting project with the aim of identifying the most relevant topics in MS healthcare by evaluating research questions that should be addressed in future systematic reviews.

We are happy to announce a major accomplishment in our collaboration with the MS International Federation (MSIF): rituximab, glatiramer acetate and cladribine are the first-ever disease-modifying therapies for people with multiple sclerosis included in the WHO Essential Medicines List (EML).